Biosimilars offer a cost-effective solution to reduce healthcare costs while maintaining efficacy and safety. However, their uptake faces barriers such as patent litigation delaying market entry, and concerns about safety and efficacy. Strategies to increase biosimilars uptake include streamlining the approval process, educating healthcare professionals and patients, and fostering competition. The international experience attests to the cost-effectiveness of biosimilars, notably with significant savings in Europe and projected savings in the US.
M&S issues update as crippling nationwide IT outage still ongoing – The Sun
Marks & Spencer (M&S) halted online orders in the UK and Ireland following a cyber attack, leading to a 5% drop in share price. Physical
